Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ap­proval

A mor­phine de­riv­a­tive — usu­al­ly in­ject­ed or in­fused — used to treat “off” episodes in Parkin­son’s is now up for grabs in a con­ve­nient un­der-the-tongue dis­solv­able for­mu­la­tion, mak­ing life much eas­i­er for pa­tients when flares strike.

Sunovion, a com­pa­ny formed in 2009 by the fu­sion of Sepra­cor and the US op­er­a­tions of Sum­it­o­mo Dainip­pon Phar­ma, has se­cured the ap­proval of the sub­lin­gual for­mu­la­tion about a year and a half fol­low­ing an ini­tial re­jec­tion by the FDA.

The drug, known chem­i­cal­ly as apo­mor­phine, is a dopamine ag­o­nist. Parkin­son’s, a chron­ic neu­rode­gen­er­a­tive dis­ease, oc­curs due to the loss of dopamine-pro­duc­ing cells. De­spite stan­dard ther­a­py with oral lev­odopa/car­bidopa, with­in the first four to six years af­ter di­ag­no­sis up to 60% of pa­tients ex­pe­ri­ence “off” episodes, which are char­ac­ter­ized by tremor, stiff­ness, slowed move­ment or oth­er mo­tor symp­toms.

Brand­ed as Kyn­mo­bi, the for­mu­la­tion is the first and on­ly sub­lin­gual ther­a­py for acute use in “off” episodes as­so­ci­at­ed with Parkin­son’s — it can be used up to five times a day. The for­mu­la­tion is set to launch by Sep­tem­ber.

The FDA ap­proval was based on a 109-pa­tient place­bo-con­trolled study. Da­ta showed Kyn­mo­bi in­duced sig­nif­i­cant im­prove­ments in mo­tor symp­toms at 30 min­utes af­ter dos­ing at week 12, with a mean re­duc­tion of 7.6 points, com­pared to place­bo, on a key Parkin­son’s dis­ease rat­ing scale. How­ev­er, near­ly a third of pa­tients (9 out of 54 on the Kyn­mo­bi arm) dis­con­tin­ued treat­ment pri­mar­i­ly be­cause of oropha­ryn­geal (the part of the throat just be­hind the mouth) side-ef­fects.

Un­til now, apo­mor­phine was ap­proved for use pack­aged as a pre-filled dis­pos­able pen to be in­ject­ed as need­ed, or as an in­fu­sion giv­en over a pe­ri­od of sev­er­al hours via a portable, bat­tery-dri­ven pump us­ing a pre-filled sy­ringe or from glass vials called am­poules.

Sunovion got its hands on the for­mu­la­tion by ac­quir­ing the biotech Cy­nap­sus Ther­a­peu­tics at a pre­mi­um — pay­ing $624 mil­lion in cash at $40.50 per share in 2016, twice the val­ue of the Toron­to-based com­pa­ny’s shares on the day. And de­spite post­ing pos­i­tive late-stage da­ta on the for­mu­la­tion in 2018, the FDA re­ject­ed its mar­ket­ing ap­pli­ca­tion in 2019. The agency re­quest­ed more in­for­ma­tion and analy­ses, al­though the com­pa­ny said no new clin­i­cal stud­ies were re­quired.

Aque­s­tive Ther­a­peu­tics, which is fo­cused on de­vel­op­ing less-in­va­sive drug de­liv­ery tech­nol­o­gy, en­tered in­to a li­cense agree­ment with Cy­nap­sus Ther­a­peu­tics in 2016. With the ap­proval of Kyn­mo­bi, the New Jer­sey-based com­pa­ny is el­i­gi­ble to get roy­al­ties on sales.

A com­pa­ny in neigh­bor­ing New York called Acor­da Ther­a­peu­tics launched an in­haled ver­sion of lev­odopa in Feb­ru­ary last year af­ter the FDA ap­proved the ther­a­py, brand­ed In­bri­ja, in late 2018 for ‘off’ episodes ex­pe­ri­enced by Parkin­son’s pa­tients.

Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point in the process

Back during the lead up to the $74 billion buyout of Celgene, the big biotech’s leadership did a little housecleaning with a major pact it had forged with Jounce. Out went the $2.6 billion deal and a collaboration on ICOS and PD-1.

Celgene, though, also added a $530 million deal — $50 million up front — to get the worldwide rights to JTX-8064, a drug that targets the LILRB2 receptor on macrophages.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How long will the mo­nop­oly last?

In 2011, GlaxoSmithKline’s Benlysta became the first biologic to win approval for lupus patients. Nine years on, the British drugmaker has unveiled detailed positive results from a study testing the drug in lupus patients with associated kidney disease — a post-marketing requirement from the initial FDA approval.

Lupus is a drug developer’s nightmare. In the last six decades, there has been just one FDA approval (Benlysta), with the field resembling a graveyard in recent years with a string of failures including UCB and Biogen’s late-stage flop, as well as defeats in Xencor and Sanofi’s programs. One of the main reasons the success has eluded researchers is because lupus, akin to cancer, is not just one disease — it really is a disease of many diseases, noted Al Roy, executive director of Lupus Clinical Investigators Network, an initiative of New York-based Lupus Research Alliance that claims it is the world’s leading private funder of lupus research, in an interview.

Fangliang Zhang, AP Images

UP­DAT­ED: Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

Amid a flurry of splashy pandemic IPOs, a J&J-partnered Chinese biotech has emerged with one of the largest public raises in biotech history.

Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on NASDAQ. The biotech had originally filed for a still-hefty $350 million, based on a range of $18-$20, but managed to fetch $23 per share, allowing them to well-eclipse the massive raises from companies like Allogene, Juno, Galapagos, though they’ll still fall a few dollars short of Moderna’s record-setting $600 million raise from 2018.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.

The offer was well-timed. Xerava was approved in 2018, four years after Tetraphase posted its first batch of pivotal trial data, and sales were nowhere near where they needed to be in order for the company to keep its head above water.

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

Lonza chairman Albert Baehny took his time headhunting a new CEO for the company, making it absolutely clear he wanted a Big Pharma or biotech CEO with a good long track record in the business for the top spot. In the end, he went with the gold standard, turning to Roche’s ranks to recruit Pierre-Alain Ruffieux for the job.

Ruffieux, a member of the pharma leadership team at Roche, spent close to 5 years at the company. But like a small army of manufacturing execs, he gained much of his experience at the other Big Pharma in Basel, remaining at Novartis for 12 years before expanding his horizons.

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

Another Big Pharma is entering the Covid-19 antibody hunt.

AbbVie has announced a collaboration with the Netherlands’ Utrecht University and Erasmus Medical Center and the Chinese-Dutch biotech Harbour Biomed to develop a neutralizing antibody that can treat Covid-19. The antibody, called 47D11, was discovered by AbbVie’s three partners, and AbbVie will support early preclinical work, while preparing for later preclinical and clinical development. Researchers described the antibody in Nature Communications last month.

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

Leen Kawas, Athira CEO (Athira)

Can a small biotech suc­cess­ful­ly tack­le an Ever­est climb like Alzheimer’s? Athi­ra has $85M and some in­flu­en­tial back­ers ready to give it a shot

There haven’t been a lot of big venture rounds for biotech companies looking to run a Phase II study in Alzheimer’s.

The field has been a disaster over the past decade. Amyloid didn’t pan out as a target — going down in a litany of Phase III failures — and is now making its last stand at Biogen. Tau is a comer, but when you look around and all you see is destruction, the idea of backing a startup trying to find complex cocktails to swing the course of this devilishly complicated memory-wasting disease would daunt the pluckiest investors.